Financially, Verve has a market cap of $475mn, cash balance of $540mn, and a cash runway of 7-8 quarters. Find out my ...

Verve Therapeutics has started dosing patients in a phase 1b trial of its in vivo gene-editing drug for high cholesterol, designed to permanently switch off the PCSK9 gene with a one-shot treatment.

Heart disease is one of the leading causes of death worldwide, and while lifestyle choices like diet, exercise, and smoking ...

Detailed price information for Verve Therapeutics Inc (VERV-Q) from The Globe and Mail including charting and trades.

In the trial, 20% of patients didn’t respond well to the PCSK9 inhibitor—could genetic markers be used to tailor therapy?

The company has launched a competition to offer grants of up to $100,000 to multiple projects that can uncover "new insights about the role of the PCSK9 protein/gene in health and disease", with a ...

PCSK9 Program Enrollment Ongoing in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102 VERVE-102 is a novel, investigational gene editing medicine designed to be a single course treatment that ...

VERVE-102 is a novel, investigational gene editing medicine designed to be a single course treatment that permanently turns off the PCSK9 gene in the liver and durably reduces disease-driving ...

Familial hypercholesterolemia results from gene mutations approximately halving ... decreased transintestinal cholesterol excretion. PCSK9, which mediates post-translational destruction of LDL ...

The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the ...